Back Back
Cell No. : Cell Name
RCB2348 : NOS-10  update : 2023/10/16
CommentHuman cell line derived from osteosarcoma.
Comment from the depositor
Terms and conditionsA prior written permission of the approver(Depositor) is necessary for any kind of use including academic use and for-profit use.
approver's address
Niigata university
Graduate School of Medical and Dental Sciences
757, 1-bancho, asahimachidori, cyuo-ku, niigata-city, Niigata Japan
Fax. +81-25-227-0782
Order Form Order Form(C-0005.pdf)   Approval Form(C-0006.pdf)   MTA(C-0007.pdf)   MTA(C-0007p.pdf)  
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (
Basic information Depositor Kawashima, Hiroyuki
Originator Kawashima, Hiroyuki
Year of deposit 2006
Animal _human < Mammals
Genus Homo
Species sapiens
Gender Male
Age at sampling 15 years
Tissue femur
Disease name osteosarcoma
Metastatic ability Yes
Metastatic tissue lymph node
Classification cancer
Year of origin 1999
Lifespan infinite
Morphology epithelial-like
Cellosaurus(Expasy) CVCL_4663
deposit info
lot info
Medium Medium List
Culture type Adherent cells
Culture medium RPMI1640 + 10% FBS
Antibiotics Free
Passage method 0.25% Trypsin
Culture information Passage ratio 1 : 8 split
SC frequency Subculture : 2 times/week
Temperature 37 ℃
CO2 concentration 5 %
Freeze medium Medium + 10% DMSO
Freezing method Slow freezing
Mycoplasma (-)
Isozyme LD, NP
STR(human) OK
deposit info
lot info
Reference information Reference 0
User's Publication 5

To topTop

To topTop
User's Publication
17096  Takemoto A, Takagi S, Ukaji T, Gyobu N, Kakino M, Takami M, Kobayashi A, Lebel M, Kawaguchi T, Sugawara M, Tsuji-Takayama K, Ichihara K, Funauchi Y, Ae K, Matsumoto S, Sugiura Y, Takeuchi K, Noda T, Katayama R, Fujita N.  Targeting Podoplanin for the Treatment of Osteosarcoma  Clin Cancer Res  2022  28(12):2633-2645  PubMed ID: 35381070   DOI: 10.1158/1078-0432.CCR-21-4509
13409  Hirozane T, Masuda M, Sugano T, Sekita T, Goto N, Aoyama T, Sakagami T, Uno Y, Moriyama H, Sawa M, Asano N, Nakamura M, Matsumoto M, Nakayama R, Kondo T, Kawai A, Kobayashi E, Yamada T.  Direct conversion of osteosarcoma to adipocytes by targeting TNIK.  JCI Insight  2021    PubMed ID: 33400690   DOI: 10.1172/jci.insight.137245
15919  Takagi S, Sasaki Y, Koike S, Takemoto A, Seto Y, Haraguchi M, Ukaji T, Kawaguchi T, Sugawara M, Saito M, Funauchi Y, Ae K, Matsumoto S, Fujita N, Katayama R.  Platelet-derived lysophosphatidic acid mediated LPAR1 activation as a therapeutic target for osteosarcoma metastasis  Oncogene  2021  40(36):5548-5558  PubMed ID: 34302117   DOI: 10.1038/s41388-021-01956-6
10919    Antitumor activities of BIBF 1120, BI 860585, and BI 836845 in preclinical models of sarcoma  Integr Mol Med  2016  3: 755-760    DOI: 10.15761/IMM.1000239
6428  Arai K, Sakamoto R, Kubota D, Kondo T.  Proteomic approach toward molecular backgrounds of drug resistance of osteosarcoma cells in spheroid culture system.  Proteomics  2013  13(15):2351-60  PubMed ID: 23712969   DOI: 10.1002/pmic.201300053

Back Back Return Top Page